This is the first update to the original CTS communication distributed on July 6th. As previously communicated, all CTS healthcare partners will remain on the Grifols ZIKV clinical trial until at least the end of October 2018, which coincides with the end of the WNV season.
Check out the Communication page for the complete details on the NAT ZIKV test update or by clicking the link: Communications
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...